Candida krusei Infections
Clinical Evaluation and Diagnosis
- The presence of C. krusei in urine with cycling fevers in a patient requires urgent evaluation to distinguish between asymptomatic candiduria, symptomatic urinary tract infection, or disseminated candidiasis with urinary involvement, according to the Infectious Diseases Society of America 1
- The correlation between candiduria and fever depends critically on the presence of urinary symptoms, which suggests true UTI rather than colonization, as stated by the Clinical Infectious Diseases society 2
- Neutropenia status is also a critical factor, as candiduria may represent disseminated candidiasis even without urinary symptoms, according to the Infectious Diseases Society of America 1, 2
- The presence of an indwelling urinary catheter makes colonization more likely than infection, as noted by the Clinical Infectious Diseases society 2
Treatment Guidelines
- For C. krusei cystitis or pyelonephritis, amphotericin B deoxycholate 0.3-0.6 mg/kg IV daily for 1-7 days is the preferred treatment due to C. krusei's intrinsic fluconazole resistance, as recommended by the Clinical Infectious Diseases society 2
- Alternative options include voriconazole at 6 mg/kg IV twice daily for 2 doses, then 3 mg/kg twice daily, as licensed in Europe for fluconazole-resistant Candida including C. krusei, according to the Clinical Infectious Diseases society 4
- Echinocandins (caspofungin, micafungin, anidulafungin) are active against C. krusei but achieve minimal urinary concentrations and should be reserved for cases where amphotericin B cannot be used, as stated by the Clinical Infectious Diseases society 4, 3
- Treatment duration should continue for 2 weeks after symptom resolution and negative urine cultures, as recommended by the Clinical Infectious Diseases society 2
Management of Special Cases
- For neonates with disseminated candidiasis, amphotericin B deoxycholate 1 mg/kg daily is recommended, according to the Clinical Infectious Diseases society 3, 5
- For older children, adult dosing guidelines apply with weight-based adjustments, as noted by the Clinical Infectious Diseases society 5
- An echinocandin is preferred for invasive C. krusei infection, with options including caspofungin, micafungin, and anidulafungin, as recommended by the Clinical Infectious Diseases society 4, 3, 5
Monitoring and Follow-Up
- Obtain follow-up urine cultures to document clearance of infection, as recommended by the Clinical Infectious Diseases society 2
- Monitor for clinical improvement within 48-72 hours of initiating therapy, as noted by the Clinical Infectious Diseases society 3
- If fever persists despite appropriate therapy, obtain imaging to identify fungus balls, abscesses, or anatomical abnormalities, as recommended by the Clinical Infectious Diseases society 2